argenx SE's shares fell nearly 15% after it discontinued its Phase 3 UNITY trial of Vyvgart for Sjögren's disease due to futility, as the study failed to meet its primary endpoint of improving systemic disease activity. The decision came earlier than expected, surprising investors and leading to a price target cut by analysts. However, argenx reported positive Phase 2 results for FB102 in celiac disease, which met its primary endpoint and will advance to Phase 3 trials. The mixed news highlights challenges and progress in argenx's drug development pipeline.
The story on argenx shares follows a day when most health-sector stocks on Pluang declined. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 08, 2026 23:11 WIB: out of 128 priced US health stocks, 107 fell and only 20 rose. Summit Therapeutics Inc (SMMT) dropped 5.99% to USD 16.88, Relay Therapeutics Inc (RLAY) fell 5.79% to USD 16.91, while Hims and Hers Health Inc (HIMS) declined 5.18% to USD 28.01 with a typical hold time of 21 days and 100% buy order activity on Pluang.
Pacira BioSciences was downgraded from Buy to Hold by Needham following Viatris's announcement to acquire the company for $36.50 per share, valuing it at about $1.65 billion. The deal is expected to close by late 2026 and will enhance Viatris's portf...
Seaport Global increased Shopify's price target from $175 to $180, reflecting an 8.3% upside from the current price of $166.16. Shopify's shares have surged 80% since May, pushing its market value above $205 billion. The rally is driven by a strategi...
Tesco reported earnings per share of $0.69, beating estimates of $0.64, despite revenue falling short at $44.60 billion versus $49.60 billion expected. The UK supermarket raised its full-year adjusted operating profit forecast to £3.15-3.30 billion, ...
CIQ has released Fuzzball 4.3, a platform that enables enterprises to deploy validated open-weight AI models and agents on their existing GPU infrastructure with a single command. This update simplifies operationalizing AI by automatically connecting...
As of September 30, 2026, Societe Generale's share capital consists of 739,264,232 shares with a total of 821,169,560 voting rights. The bank highlights its strong global presence with 110,000 employees serving 27 million clients across 58 countries....
